Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
491.34
+11.16 (2.32%)
At close: Jun 26, 2026, 4:00 PM EDT
489.42
-1.92 (-0.39%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 563.58, with a low estimate of 436 and a high estimate of 641. The average target predicts an increase of 14.70% from the current stock price of 491.34.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock from 33 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 21 | 22 | 21 | 21 | 21 |
| Buy | 4 | 4 | 5 | 5 | 6 | 6 |
| Hold | 6 | 5 | 4 | 5 | 5 | 5 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 31 | 32 | 33 | 32 | 33 | 33 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 24, 2026 |
Unknown Analyst Raymond James No rating | Raymond James | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Jun 24, 2026 |
| Barclays | Barclays | Buy Maintains $615 | Buy | Maintains | $615 | +25.17% | Jun 22, 2026 |
| Citi | Citi | Buy Maintains $585 | Buy | Maintains | $585 | +19.06% | Jun 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $550 | Buy | Maintains | $550 | +11.94% | Jun 12, 2026 |
Financial Forecast
Revenue This Year
13.04B
from 12.00B
Increased by 8.64%
Revenue Next Year
14.27B
from 13.04B
Increased by 9.42%
EPS This Year
19.15
from 18.40
Increased by 4.05%
EPS Next Year
21.47
from 19.15
Increased by 12.15%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.1B | 16.2B | |
| Avg | 13.0B | 14.3B | |
| Low | 13.0B | 13.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 9.2% | 24.3% | |
| Avg | 8.6% | 9.4% | |
| Low | 7.9% | 2.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 20.73 | 24.64 | |
| Avg | 19.15 | 21.47 | |
| Low | 18.42 | 18.77 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 12.7% | 28.7% | |
| Avg | 4.1% | 12.1% | |
| Low | 0.1% | -2.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.